EDIT Insider Trading

Editas Medicine, Inc. (EDIT) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $375.2M, listed on NASDAQ, employing roughly 87 people, carrying a beta of 2.00 to the broader market. Editas Medicine, Inc. Led by Gilmore O'Neill, public since 2016-02-03.

In the last 12 months, Editas Medicine, Inc. insiders made 0 buy transactions and 14 sale transactions.

DateNameTypeSharesPriceValue
Sep 9, 2026Ory Daniel ScottA-Award950,000$3.03$2.9M
Sep 9, 2026Ory Daniel Scott0$0.00$0
Sep 4, 2026Burkly LindaS-Sale709$3.04$2.2K
Sep 4, 2026Parison AmyS-Sale453$3.04$1.4K
Sep 4, 2026O'Neill Gilmore NeilS-Sale5,124$3.04$15.6K
Aug 7, 2026Ellinor Patrick Thomas IIA-Award103,400$2.90$299.9K
Aug 7, 2026Ellinor Patrick Thomas II0$0.00$0
Aug 5, 2026Parison AmyS-Sale678$2.58$1.7K
Jul 29, 2026Burkly LindaS-Sale4,928$2.67$13.2K
Jun 22, 2026Connaughton BernadetteA-Award51,700$2.55$131.8K

EDIT Insider Activity by Quarter

Reported Form 4 and Form 5 lines under EDIT's own SEC company ID, by transaction date, back to Q4 2024. Purchases and sales are code P / S (open market or private) in the company's shares; other lines are purchases and sales of other securities (options, warrants, preferred), awards, exercises, tax withholding, gifts and other acquisitions and dispositions. Later filings and amendments can change the current quarter. Earlier quarters are not shown: the filings read reach back to Mar 17, 2017, and a quarter counts only when every filing for it was read.

QuarterPurchasesBoughtSalesSoldOther Lines
Q4 2026 (so far)0N/A0N/A0
Q3 20260N/A5$34.0K2
Q2 20260N/A3$44.8K5
Q1 20260N/A3$13.4K3
Q4 20250N/A3$14.6K0
Q3 20250N/A5$32.1K0
Q2 20250N/A3$28.2K6
Q1 20250N/A3$40.4K6
Q4 20240N/A2$4.5K0

EDIT Institutional Ownership (13F)

As of Jun 30, 2026 (Q2 2026), 215 institutions reported holding 120,320,385 EDIT shares, valued at $389.6M as reported, 139.7% of its market cap (market cap of Jun 26, 2026). That is +7 institutions from the quarter before. Among managers whose reports for both quarters are comparable, 35 opened a position, 21 closed one, 76 added and 41 trimmed.

Top Holders, Q2 2026

ManagerSharesValueChange
TCG Crossover Management, LLC11,111,111$36.0MNew
BlackRock, Inc.10,589,990$34.3M+1,326,678
RA CAPITAL MANAGEMENT, L.P.8,889,000$28.8MNew
Commodore Capital LP8,889,000$28.8MNew
ADAR1 Capital Management, LLC8,889,000$28.8MNew
VANGUARD CAPITAL MANAGEMENT LLC6,141,336$19.9M+1,936,967
Paradigm Biocapital Advisors LP5,586,625$18.1MNew
Opaleye Management Inc.3,861,930$12.5M+1,934,933
VANGUARD PORTFOLIO MANAGEMENT LLC3,598,339$11.7M+449,769
Woodline Partners LP3,555,497$11.5MNew

By Quarter

QuarterInstitutionsSharesValue
Q2 2026215120,320,385$389.6M
Q1 202620851,834,941$127.5M
Q4 202519750,061,386$102.7M
Q3 202519343,864,307$152.2M
Q2 202519341,644,904$91.6M
Q1 202519444,051,066$51.1M
Q4 202420351,039,325$64.8M
Q3 202422755,902,189$190.4M
Q2 202423358,104,972$271.3M

From the SEC's Form 13F data sets: investment managers with $100 million or more in Section 13(f) securities report their holdings each quarter, up to 45 days after it ends; a restated filing replaces the original, and values are as the managers reported them (a position whose price runs about 1,000 times below other managers', from a manager whose positions mostly do, is read as reported in thousands of dollars). The same shares can be reported by more than one manager, so totals can count some twice.

ETFs Holding EDIT

FundWeight of EDITShares (as reported)Value (as reported)Source updated
VTI Vanguard Morningstar Total Stock Market ETF0.00%4,890,144$15.0MOct 7, 2026
XBI State Street SPDR S&P Biotech ETF0.12%4,286,358$12.0MOct 8, 2026
IWM iShares Russell 2000 ETF0.01%4,036,732$11.1MOct 8, 2026
IWO iShares Russell 2000 Growth ETF0.03%1,307,227$3.6MOct 8, 2026
VXF Vanguard Extended Market ETF0.00%1,145,502$3.5MOct 7, 2026
IBB iShares Biotechnology ETF0.03%1,047,734$2.9MOct 8, 2026
SCHA Schwab U.S. Small-Cap ETF0.01%695,679$1.9MOct 8, 2026
VTWO Vanguard Russell 2000 ETF0.01%576,017$1.8MOct 7, 2026
IWC iShares Micro-Cap ETF0.10%495,337$1.4MOct 8, 2026
VHT Vanguard Health Care ETF0.01%435,255$1.3MOct 7, 2026
LABU Direxion Daily S&P Biotech Bull 3X Shares0.03%197,737$543.8KOct 8, 2026
PRFZ Invesco RAFI US 1500 Small-Mid ETF0.02%169,610$466.4KOct 8, 2026
VTWG Vanguard Russell 2000 Growth ETF0.02%97,628$298.7KOct 7, 2026
SCHB Schwab U.S. Broad Market ETF0.00%98,177$267.6KOct 8, 2026
AVUS Avantis U.S. Equity ETF0.00%76,212$209.6KOct 8, 2026

From each fund's latest holdings file on record that shows EDIT's listed security itself. A file counts when its line count is consistent with the fund's reported holdings count (at most twice it plus 10, or at most 1,000 lines for a reported count of exactly 10, which the data source gives many funds as a cap), read with that file or inherited from the fund's last classified file (within 20% of its line count, read within 60 days). Funds whose line for the company could not be confirmed as EDIT's listed security, or that hold it through underlying funds (look-through), are not listed. Only long positions count: a fund is left out when any of its lines for EDIT reports a negative weight, share count or value, or none of them above zero (a short position, or figures that disagree). Shares, value and weight are as reported in each fund's file, dated by the data source's last update of that file (not the date of the positions); the weight is EDIT's share of that fund.

EDIT Congress Trades

Members of Congress and their households disclosed 3 transactions in EDIT on file (1 purchases, 2 sales) by 2 members, the latest trade on Apr 10, 2023.

MemberChamberTypeAmountTradedDisclosed
Daniel S. Goldman (D-NY-10)HouseSale$1,001 - $15,000Apr 10, 2023May 19, 2023
James M. Inhofe (R-OK)SenateSale (Full)$15,001 - $50,000Feb 4, 2019Feb 24, 2019
James M. Inhofe (R-OK)SenatePurchase$15,001 - $50,000Oct 19, 2017Nov 7, 2017

From the periodic transaction reports members of the Senate and the House file under the STOCK Act, within 45 days of a trade (some file later); amounts are the ranges the reports give (a few give an exact amount), and a transaction a later report lists again is counted once. On file: House reports disclosed from Apr 10, 2023 through Oct 13, 2026; Senate reports disclosed from Jan 30, 2014 through Oct 7, 2026. The party is the member's on the trade date. A trade is listed under the company that traded under its ticker on the trade date (dated from Feb 1, 2021, unless the filing describes another company of ours; before that, only when the filing's description of the security is the company's name).

How to Read EDIT Insider Activity

Net insider sentiment skews to the sell side over the trailing twelve months: 14 sales versus 0 buys. Insider sales carry less informational weight than buys because they are often driven by liquidity, tax planning, or pre-scheduled Rule 10b5-1 trading plans rather than negative information. The transaction type alone does not say whether a sale was made on the open market or privately, or under a 10b5-1 plan; the filing's plan checkbox and footnotes do. The transaction table above includes the filer's reporting name, transaction type, share count, per-share price, and total dollar value where computable. For options traders, insider activity is one input to event-driven sizing alongside earnings calendar, analyst-rating cluster moves, and the implied-vol surface. Form 4 filings (the dominant Section 16 reporting form) must be submitted within two business days of the transaction; clusters of buys across multiple insiders within a short window are the strongest informational pattern. SEC EDGAR carries the underlying source filings for verification and additional historical depth.

Learn how insider trading is reported and how to read the data →

Frequently asked EDIT insider trading questions

How active are EDIT insiders right now?
Over the trailing twelve months, Editas Medicine, Inc. (EDIT) insiders made 0 buy transactions and 14 sale transactions. Net insider sentiment over the trailing twelve months tilts to the sell side (14 sales vs 0 buys). The transaction list above shows the most recent filings; each entry includes the insider's name, transaction type, share count, and per-share price.
What counts as an insider transaction?
Section 16 of the Securities Exchange Act requires officers, directors, and 10% beneficial-owner shareholders to disclose changes in their holdings via Form 3 (initial statement), Form 4 (subsequent transactions, filed within two business days), and Form 5 (annual catch-up). Insider transactions cover open-market purchases and sales, exercise of stock options, gifts, and grants. The "transaction type" field on each row distinguishes these subcategories.
Are EDIT insider buys a bullish signal?
Insider purchases (Type P, made on the open market or privately; the code covers both) carry more informational weight than insider sales: an insider must commit personal capital, and the SEC scrutinizes purchases under Rule 10b5-1 for material non-public information. Sales, by contrast, are often driven by liquidity, tax planning, or pre-scheduled 10b5-1 trading plans rather than negative information. Cluster buying (multiple insiders buying within a short window) is a stronger signal than isolated buys.
How do EDIT insider transactions affect options pricing?
Insider transaction data does not directly drive implied volatility, but Form 4 disclosures can move single-name IV if the size or timing is unusual (e.g. a large CEO buy ahead of an earnings window). Options markets price the marginal informational content; routine transactions under pre-scheduled plans are typically ignored. For event-driven options sizing, pair the insider transaction history with the upcoming earnings calendar.